Michael J. Klag, MD, MPH, dean of the Johns Hopkins Bloomberg School of Public Health, has awarded the Dean's Medal-the School's highest honor-to William Foege, MD, MPH. Foege is a celebrated epidemiologist and physician who played a leading role in many of the important public health campaigns of the past half-century, including efforts to eradicate smallpox and to control onchocerciasis (the cause of river blindness) and guinea worm.
[More]
"The World Health Organization reports Guinea worm disease, which has plagued people for thousands of years, is on the verge of eradication," VOA News reports. "The U.N. agency says fewer than 400 cases of the infectious parasitic disease exist in four African countries, and that it will soon become only the second, after smallpox, to be wiped off the face of the earth," the news service writes.
[More]
The Washington Post examines global efforts to eradicate Guinea worm disease, writing, "The parasitic infection which has sickened millions, mostly in Asia and Africa, is on the verge of being done in not by sophisticated medicine but by aggressive public health efforts in some of the poorest and most remote parts of the world."
[More]
The idea that disease and infection might be used as weapons is truly dreadful, but there is plenty of evidence showing that biological weapons have been around since ancient times. Bioterrorism, as it is dubbed, is nothing new, and although medicines have made the world a safer place against a myriad of old scourges both natural and manmade, it still remains all too easy today to uncork a nasty cloud of germs.
[More]
Scientists have discovered that poxviruses, which are responsible for smallpox and other diseases, can adapt to defeat different host antiviral defenses by quickly and temporarily producing multiple copies of a gene that helps the viruses to counter host immunity.
[More]
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today it has received notification from the U.S. Food and Drug Administration (FDA) that its SparVax rPA anthrax vaccine program has been placed on clinical hold.
[More]
Lawrence Altman, former senior medical correspondent for the New York Times, writes in an opinion analysis in the newspaper that while there was much discussion about "ending the AIDS epidemic" and an "AIDS-free generation" at the XIX International AIDS Conference (AIDS 2012) last week in Washington, D.C., "[o]ne obstacle is a failure to clearly define the epidemic or what it means to have an AIDS-free generation."
[More]
Chimerix, Inc. today announced the execution of a license agreement granting Merck, known as MSD outside the United States and Canada, exclusive worldwide rights to CMX157, Chimerix's novel lipid acyclic nucleoside phosphonate currently being evaluated to treat HIV infection.
[More]
Polio is a disease caused by a virus and results in paralysis, usually in the legs, of those affected. The paralysis is irreversible. In some extreme cases the virus spreads to the nerve cells of the brain reducing breathing capacity and this rarer form can be fatal.
[More]
Ventria Bioscience today announced that its non-therapeutic products division InVitria has been awarded a new Small Business Innovation Research Program (SBIR) grant from the National Institutes of Health, National Institute of Allergy and Infectious Diseases.
[More]
While vaccines are perhaps medicine's most important success story, there is always room for improvement. Researchers at Oregon Health & Science University's Oregon National Primate Research Center (ONPRC) appear to have done just that.
[More]
"[P]eople everywhere have a stake in eradicating polio, as we have stamped out smallpox," a Bloomberg View editorial states, adding, "Immunizing the last unvaccinated children on the planet is an expensive and complex undertaking, and worth it in the long run."
[More]
Infectious diseases-both old and new-continue to exact a devastating toll, causing some 13 million fatalities per year around the world. Vaccines remain the best line of defense against deadly pathogens and now Kathryn Sykes and Stephen Johnston, researchers at Arizona State University's Biodesign Institute, along with co-author Michael McGuire from the University of Texas Southwestern Medical Center are using clever functional screening methods to attempt to speed new vaccines into production that are both safer and more potent.
[More]
"In recent weeks, the emergence on the Thai-Myanmar border of malaria strains resistant to artemisinin, a plant-derived drug, have led to pessimistic headlines and reminders of the setback caused by resistance to the drug chloroquine, which began in the 1950s," columnist and author Matt Ridley writes in the Wall Street Journal's "Mind & Matter," noting, "April 25 is World Malaria Day, designed to draw attention to the planet's biggest infectious killer."
[More]
Research from The Cancer Institute of New Jersey (CINJ) shows that a series of vaccine injections given directly into a pancreatic cancer tumor is shown to be associated with stable disease in patients who are not candidates for surgery.
[More]
An immunotherapy regimen incorporating poxviruses and targeting a particular tumor antigen, NY-ESO-1, has shown promise in treating two types of cancers.
[More]
Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company's highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71.
[More]
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the year ended December 31, 2011.
[More]
Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.
[More]
Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.
[More]